Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy of multiple sclerosis: Where are we? Where should we go?

  • Commentary
  • Published:

From Nature Immunology

View current issue Submit your manuscript

Differences in multiple sclerosis patient's disease and their responses to standard drugs indicate that today's therapies need to be more individualized. It is proposed that gene expression profiling in conjunction with magnetic resonance imaging be used to optimize future treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Schematic depiction of the pathogenetic steps that lead to tissue damage in MS.
Figure 2: Longitudinal course of the fluctuations of contrast-enhancing MRI lesions in a patient who responded to IFN-β treatment.
Figure 3: Identification of responders and nonresponders to immunomodulatory treatment with IFN-β.

References

  1. Bielekova, B. & Martin, R. Curr. Treat. Options Neurol. 1, 201–219 (1999).

    Article  CAS  PubMed  Google Scholar 

  2. McFarlin, D. E. & McFarland, H. F. New Engl. J. Med. 307, 1183–1188 (1982).

    Article  CAS  PubMed  Google Scholar 

  3. McFarlin, D. E. & McFarland, H. F. New Engl. J. Med. 307, 1246–1251 (1982).

    Article  CAS  PubMed  Google Scholar 

  4. Martin, R., McFarland, H. F. & McFarlin, D. E. Annu. Rev. Immunol. 10, 153–187 (1992).

    Article  CAS  PubMed  Google Scholar 

  5. Prineas, J. W. in Handbook of Clinical Neurology, Demyelinating Diseases (eds Vinken, P. J., Bruyn, G. W., Klawans, H. L. & Koetsier, J. C.) Vol. 3 Ch. 47 213–257 (Amsterdam/New York, Elsevier Science, 1985).

    Google Scholar 

  6. Zamvil, S. S. & Steinman, L. Annu. Rev. Immunol. 8, 579–621 (1990).

    Article  CAS  PubMed  Google Scholar 

  7. Ota, K. et al. Nature 346, 183–187 (1990).

    Article  CAS  PubMed  Google Scholar 

  8. Lucchinetti, C. et al. Ann. Neurol. 47, 707–717 (2000).

    Article  CAS  PubMed  Google Scholar 

  9. McFarland, H. F. et al. Ann. Neurol. 32, 758–766 (1992).

    Article  CAS  PubMed  Google Scholar 

  10. Becker, K. G. et al. Proc. Natl Acad. Sci. USA 95, 9979–9984 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 45, 1277–1285 (1995).

  12. Johnson, K. P. et al. Neurology 45, 1268–1276 (1995).

    Article  CAS  PubMed  Google Scholar 

  13. Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I. & Hafler, D. A. J. Clin. Invest. 105, 967–976 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wandinger, K. P. et al. Ann. Neurol. 10 (in the press, 2001).

  15. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 53, 457–465 (1999).

  16. Moalem, G. et al. Nature Med. 5, 49–55 (1999).

    Article  CAS  PubMed  Google Scholar 

  17. Owens, T., Wekerle, H. & Antel, J. Nature Med. 7, 161–166 (2001).

    Article  CAS  PubMed  Google Scholar 

  18. Hohlfeld, R. Brain 120, 865–916 (1997).

    Article  PubMed  Google Scholar 

  19. Kennedy, M. K., Tan, L.-J., Dal Canto, M. C. & Miller, S. D. J. Immunol. 145, 117–126 (1990).

    CAS  PubMed  Google Scholar 

  20. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. & Kuchroo, V. K. Immunity 3, 397–405 (1995).

    Article  CAS  PubMed  Google Scholar 

  21. Bielekova, B. et al. Nature Med. 6, 1167–1175 (2000).

    Article  CAS  PubMed  Google Scholar 

  22. Kappos, L. et al. Nature Med. 6, 1176–1182 (2000).

    Article  CAS  PubMed  Google Scholar 

  23. Jacobs, L. D. et al. New Engl. J. Med. 343, 898–904 (2000).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroimmunology Branch, NINDS, National Institutes of Health, Building 10, Room 5B-16, 10 Center DR MSC 1400, Bethesda, 20892-1400, MD, USA

    Roland Martin & Henry F. McFarland

  2. Clinical Development CNS, Schering AG, Berlin, 13342, Germany

    Claus-Steffen Stürzebecher

Authors
  1. Roland Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claus-Steffen Stürzebecher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry F. McFarland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, R., Stürzebecher, CS. & McFarland, H. Immunotherapy of multiple sclerosis: Where are we? Where should we go?. Nat Immunol 2, 785–788 (2001). https://doi.org/10.1038/ni0901-785

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ni0901-785

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation